Humanetics, a Minneapolis, MN-based clinical-stage pharmaceutical company, received additional $5M in funding from Department of Defense (DOD).
The company intends to use the funds to accomplish additional manufacturing activities for both the BIO 300 drug substance and BIO 300 drug product.
Led by CEO Ronald J. Zenk, Humanetics is a clinical-stage pharmaceutical company engaged in the accelerated discovery, development, and commercialization of proprietary drugs in markets with urgent and unmet needs with a focus on medical countermeasures, radiation modulators for oncology and inflammatory lung diseases.
The company aims to develop its drug, BIO 300, as a medical countermeasure to reduce bodily harm caused by acute exposure to radiation. It is advancing BIO 300 toward a New Drug Application (NDA) submission with pre-approval for emergency use authorization (pre-EUA) application as an early access point in the event a radiological/nuclear emergency occurs prior to full approval.
FinSMEs
11/12/2024